Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 1-Year High – Still a Buy?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $13.84 and last traded at $13.6950, with a volume of 84737 shares trading hands. The stock had previously closed at $13.57.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Truist Financial set a $15.00 target price on shares of Amneal Pharmaceuticals in a report on Wednesday, January 7th. Piper Sandler restated an “overweight” rating and set a $13.00 price target (up previously from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Barclays initiated coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $15.00 price objective on the stock. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $13.80.

Amneal Pharmaceuticals Stock Up 0.8%

The business’s 50 day moving average is $12.64 and its two-hundred day moving average is $10.71. The firm has a market capitalization of $4.30 billion, a P/E ratio of 684.59 and a beta of 1.34.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings data on Thursday, October 30th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. Amneal Pharmaceuticals had a net margin of 0.20% and a negative return on equity of 185.60%. The firm had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Ted C. Nark sold 50,000 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $11.72, for a total transaction of $586,000.00. Following the sale, the director owned 291,029 shares of the company’s stock, valued at $3,410,859.88. This represents a 14.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Nikita Shah sold 131,856 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the transaction, the executive vice president owned 146,403 shares in the company, valued at $1,745,123.76. The trade was a 47.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 231,856 shares of company stock valued at $2,743,724 in the last quarter. 26.56% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Comerica Bank boosted its stake in Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after purchasing an additional 1,957 shares during the period. Exchange Traded Concepts LLC purchased a new position in Amneal Pharmaceuticals during the third quarter worth about $31,000. Spire Wealth Management lifted its position in shares of Amneal Pharmaceuticals by 66.6% during the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after buying an additional 1,023 shares in the last quarter. Focus Partners Wealth bought a new position in shares of Amneal Pharmaceuticals in the third quarter valued at approximately $42,000. Finally, Advisory Services Network LLC purchased a new position in Amneal Pharmaceuticals in the third quarter worth $50,000. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.